electroCore, Inc.
NASDAQ:ECOR · NASDAQ Capital Market
-$0.50 today
Vol 0.13M · Avg 0.11M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
817.2%
avg -7.8%
ROIC
-171.0%
avg -67.6%
ROA
-74.8%
avg -327.9%
Analysis
ROE is currently the strongest return metric at 817.2% versus its period average of -7.8%. 1 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Joshua S. Lev | CFO & Interim President | $528,900.00 | — | 41 | $84,889.00 | 1.02% |
Peter S. Staats | Chief Medical Officer | $238,415.00 | — | 62 | $84,889.00 | 1.02% |
Thomas J. Errico | Founder & Independent Chairman | $75,000.00 | — | 73 | $360,071.00 | 4.34% |
Mitch Deshon | Vice President of Sales & New Market Development | — | — | — | — | — |
Jennifer A. Hayes | Vice President of HR & Employee Success | — | — | — | — | — |
Michael Fox | Chief Operating Officer | — | — | — | $70,000.00 | 0.84% |
Amanda Yanuklis | Chief of Staff | — | — | — | — | — |
Andy Brown | Vice President & Corporate Controller | — | — | — | — | — |
Donald Melnikoff | Senior Vice President of Engineering, Regulatory & Compliance | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
4
$135,972.08
Sells
5
$202,267.32
Net Sentiment
$66,295.24
Net selling
Most Active
Lev Joshua S.
4 transactions
Analysis
Insiders reported 4 buys worth $135,972.08 and 5 sells worth $202,267.32 over the last 12 months. That adds up to net selling of $66,295.24. Lev Joshua S. was the most active insider with 4 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | +62.7% | +37.9% (10yr)3 analysts |
| Net Income | N/A | N/A | N/A | N/A3 analysts |
| EBIT | N/A | N/A | N/A | N/A3 analysts |
Analysis
Recent growth has been strongest in Revenue at +62.7% over three years. Forward estimates point to Revenue at +37.9% (10yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
MAIA Biotechnology, Inc.
AMEX:MAIA
$82.99M
Myomo, Inc.
AMEX:MYO
$50.04M
PolyPid Ltd.
PYPD
$47.85M
111, Inc.
YI
$39.66M
BioXcel Therapeutics, Inc.
BTAI
$36.75M
RenovoRx, Inc.
RNXT
$33.24M
NeuroOne Medical Technologies Corporation
NMTC
$27.85M
Hyperion DeFi, Inc.
HYPD
$17.07M
Zynex, Inc.
ZYXI
$3.80M
Vicarious Surgical Inc.
RBOT
$1.70M
Who manages ECOR?
electroCore, Inc. (ECOR) lists 9 active executives. The top listed executive is Joshua S. Lev, CFO & Interim President.
Are ECOR insiders buying or selling?
Recent insider activity shows net buying of $11.71M.
Explore More
Continue the stock analysis
Jump to another research area for this company.